Related Experiment Video
Updated: Aug 2, 2026
An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
Published on: May 8, 2020
A cost comparison of heart transplantation versus alternative operations for cardiomyopathy
J T Cope1, A K Kaza, C C Reade
1Department of Surgery, University of Virginia Health System, Charlottesville 22908, USA.
Insights
Alternative operations for cardiomyopathy offer comparable survival to heart transplantation but are significantly less expensive. These procedures, including coronary bypass and ventricular reconstruction, present a cost-effective option due to high organ procurement expenses in transplantation.
Area of Science:
- Cardiovascular Surgery
- Health Economics
Background:
- Heart transplantation is a vital therapy for cardiomyopathy, yet faces limitations due to organ scarcity and high costs.
- Alternative surgical procedures such as coronary bypass, mitral valve repair, and left ventricular reconstruction have been proposed.
Purpose of the Study:
- To compare the in-hospital costs and early outcomes of alternative surgical operations against elective heart transplantation.
- To determine the economic viability of alternative procedures in managing cardiomyopathy.
Main Methods:
- A comparative analysis of clinical and financial data from 268 patients with reduced ejection fraction (EF < 30%).
- Patients underwent either heart transplantation (n=52), coronary bypass (n=176), mitral repair (n=15), or left ventricular reconstruction (n=25).
- Statistical evaluation for significant differences between groups (p < 0.05).
Main Results:
- No significant difference in operative mortality across all groups (p = 0.8).
- Heart transplantation exhibited significantly higher total hospital costs ($75,992) compared to alternative operations (p < 0.001).
- Organ procurement expenses accounted for 39.7% of total heart transplant costs; survival rates were comparable across all procedures (p = 0.86).
Conclusions:
- Alternative surgical operations provide comparable early outcomes and long-term survival to heart transplantation.
- These alternative procedures are markedly less expensive than heart transplantation, largely due to organ procurement costs.
- Prioritizing alternative operations for cardiomyopathy is recommended when clinically feasible to mitigate costs.
Background:
Heart transplantation is an established therapy for cardiomyopathy but is limited by organ shortage and expense. As a result, alternative operations have been proposed including coronary bypass, mitral valve repair, and left ventricular reconstruction. Because it is unknown whether alternative operations are less expensive than replacing the diseased heart, we compared in-hospital costs and early outcome of these operations with elective heart transplantation.
Methods:
We compared clinical and financial data of 268 patients with ejection fraction less than 30% who underwent elective heart transplantation (n = 52, UNOS status 2 only), coronary bypass (n = 176), mitral repair (n = 15), or left ventricular reconstruction (n = 25). Data were evaluated for between-group differences, with p less than 0.05 as significant.
Results:
Preoperative ejection fraction, although similar for heart transplantation (21.2% +/- 1.3%), coronary bypass (25.8% +/- 0.4%), mitral repair (22.9% +/- 1.5%), and left ventricular reconstruction (24.2% +/- 2.1%), was significantly different between the former two (p < 0.001). There was no difference in operative mortality: 5.8% (3 of 52), 3.4% (7 of 176), 6.7% (1 of 15), and 4.0% (1 of 25), respectively (p = 0.8). However, total hospital cost of heart transplantation was significantly greater than all others: $75,992 +/- $5,380, $25,008 +/- $1,446, $32,375 +/- $2,379, and $26,584 +/- $4,076, respectively (p < 0.001). Organ procurement expenses alone comprised 39.7% ($30,169) of total transplant cost. Kaplan-Meier survival analysis failed to show any survival difference between the various groups (p = 0.86)
Conclusions:
Compared with heart transplantation, alternative operations yield a comparable early outcome and long-term survival, and are markedly less expensive. The cost of transplantation, which is largely due to procurement expenses, is yet another reason to attempt alternative operations for cardiomyopathy whenever feasible.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:28Kidney Transplant I: Introduction